SEC Form 4 · accession 0001209191-17-047371
PROTEOSTASIS THERAPEUTICS, INC. · PTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen M Boudreau
Officer — Chief Financial Officer
Period of report
Aug 1, 2017
Accepted (ET)
Aug 3, 2017 · 4:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001445283
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $2.25 | Aug 1, 2017 | A | 215,000 | A | — | Jul 25, 2027 | Common Stock | 215,000 | 215,000 | D |
Explanation of responses
- F1These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on July 25, 2018, and thereafter vesting and becoming exercisable in quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on July 25, 2021, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.